

Acquired von Willebrand Syndrome in Patients With an Device

Circulation: Heart Failure

3, 675-681

DOI: [10.1161/circheartfailure.109.877597](https://doi.org/10.1161/circheartfailure.109.877597)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Unforeseen Consequences of Therapy With Continuous-Flow Pumps. <i>Circulation: Heart Failure</i> , 2010, 3, 647-649.	1.6	42
2	Can the Occurrence of Gastrointestinal Bleeding in Nonpulsatile Left Ventricular Assist Device Patients Provide Clues for the Reversal of Arteriosclerosis?. <i>Cardiology Clinics</i> , 2011, 29, 641-645.	0.9	1
3	The 2011 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Sleep Apnea, Renal Dysfunction, Mechanical Circulatory Support, and Palliative Care. <i>Canadian Journal of Cardiology</i> , 2011, 27, 319-338.	0.8	139
4	Advances in mechanical circulatory support: Year in review. <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, 487-493.	0.3	34
5	The next decade in mechanical assist: advances that will help the patient and the doctor. <i>Current Opinion in Cardiology</i> , 2011, 26, 256-260.	0.8	4
6	Managing long-term complications of left ventricular assist device therapy. <i>Current Opinion in Cardiology</i> , 2011, 26, 237-244.	0.8	40
8	How I treat the acquired von Willebrand syndrome. <i>Blood</i> , 2011, 117, 6777-6785.	0.6	292
9	Pathophysiology of acquired von Willebrand disease: a concise review. <i>European Journal of Haematology</i> , 2011, 87, 99-106.	1.1	53
10	Acquired von Willebrand syndrome and mitral valve prosthesis leakage. A pilot study. <i>European Journal of Haematology</i> , 2011, 87, 448-456.	1.1	14
11	Durable Mechanical Circulatory Support Devices. <i>Progress in Cardiovascular Diseases</i> , 2011, 54, 132-143.	1.6	8
13	Editorial Comment: Adverse events in long-term ventricular assist device therapy. <i>European Journal of Cardio-thoracic Surgery</i> , 2012, 42, 323-324.	0.6	2
14	Bleeding and Thrombosis in Patients With Continuous-Flow Ventricular Assist Devices. <i>Circulation</i> , 2012, 125, 3038-3047.	1.6	261
15	Charting the Unfamiliar. <i>ASAIO Journal</i> , 2012, 58, 296.	0.9	0
16	<i>Circulation: Heart Failure</i> Editorsâ€™ Picks. <i>Circulation: Heart Failure</i> , 2012, 5, .	1.6	0
17	Cerebrovascular complications of left ventricular assist devices. <i>European Journal of Cardio-thoracic Surgery</i> , 2012, 42, 612-620.	0.6	77
18	Approach to the Diagnosis and Management of Common Bleeding Disorders. <i>Seminars in Thrombosis and Hemostasis</i> , 2012, 38, 711-719.	1.5	18
19	Continuousâ€flow left ventricular assist device support in patients with advanced heart failure: points of interest for the daily management. <i>European Journal of Heart Failure</i> , 2012, 14, 351-356.	2.9	34
20	Mechanical Circulatory Support for Advanced Heart Failure. <i>Circulation</i> , 2012, 125, 1304-1315.	1.6	182

#	ARTICLE	IF	CITATIONS
21	The Pharmacotherapy Implications of Ventricular Assist Device in the Patient With End-Stage Heart Failure. <i>Journal of Pharmacy Practice</i> , 2012, 25, 232-249.	0.5	6
23	Should Left Ventricular Assist Device Be Standard of Care for Patients With Refractory Heart Failure Who Are Not Transplantation Candidates?. <i>Circulation</i> , 2012, 126, 3088-3094.	1.6	7
24	Continuous flow left ventricular assist devices and gastrointestinal bleeding. <i>International Journal of Critical Illness and Injury Science</i> , 2012, 2, 47.	0.2	1
25	What is the optimal anticoagulation in patients with a left ventricular assist device?. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2012, 15, 733-740.	0.5	73
26	Management of Implantable Assisted Circulation Devices. <i>Cardiology Clinics</i> , 2012, 30, 673-682.	0.9	6
27	Why Is My Patient Bleeding Or Bruising?. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 321-344.	0.9	14
28	Diagnosis and treatment of acquired von Willebrand syndrome. <i>Thrombosis Research</i> , 2012, 130, S2-S6.	0.8	81
29	Newer-generation ventricular assist devices. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2012, 26, 117-130.	1.7	35
30	Postoperative care and complications after ventricular assist device implantation. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2012, 26, 231-246.	1.7	24
31	Coagulation management in patients undergoing mechanical circulatory support. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2012, 26, 179-198.	1.7	77
32	Pulsed or continuous flow in long-term assist devices: a debated topic. <i>Transplantation Reviews</i> , 2012, 26, 241-245.	1.2	7
33	Outcomes in Advanced Heart Failure Patients With Left Ventricular Assist Devices for Destination Therapy. <i>Circulation: Heart Failure</i> , 2012, 5, 241-248.	1.6	322
34	We Always Need a Pulse, Or Do We??. <i>Journal of Cardiovascular Translational Research</i> , 2012, 5, 296-301.	1.1	7
35	Factor VIII/von Willebrand factor concentrate therapy for ventricular assist device-associated acquired von Willebrand disease. <i>Transfusion</i> , 2012, 52, 1535-1541.	0.8	24
36	Ventricular assist devices: Pharmacological aspects of a mechanical therapy. , 2012, 134, 189-199.		15
37	Advances and Future Directions for Mechanical Circulatory Support. <i>Anesthesiology Clinics</i> , 2013, 31, 321-353.	0.6	7
38	Impact of Adverse Events on Ventricular Assist Device Outcomes. <i>Current Heart Failure Reports</i> , 2013, 10, 89-100.	1.3	23
39	Translational Approach to Heart Failure. , 2013, , .		3

#	ARTICLE	IF	CITATIONS
41	The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: Executive summary. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, 157-187.	0.3	1,225
43	Mechanical circulatory support: devices, outcomes and complications. <i>Heart Failure Reviews</i> , 2013, 18, 35-53.	1.7	37
44	Time course of acquired von Willebrand disease associated with two types of continuous-flow left ventricular assist devices: HeartMate II and CircuLite Synergy Pocket Micro-pump. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, 539-545.	0.3	52
45	Total Knee Arthroplasty in Patients With a Left Ventricular Assist Device. <i>Journal of Arthroplasty</i> , 2013, 28, 376.e1-376.e3.	1.5	4
46	Major Bleeding During HeartMate II Support. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2188-2196.	1.2	62
47	Indexes of von Willebrand Factor as Biomarkers of Aortic Stenosis Severity (from the Biomarkers of) Tj ETQq1 1 0.784314 rgBT /Overl 0.7	0.7	45
48	Acquired Disorders of Platelet Function. , 2013, , 1049-1073.		3
49	Evaluation of platelet aggregability during left ventricular bypass using a MedTech MagLev VAD in a series of chronic calf experiments. <i>Journal of Artificial Organs</i> , 2013, 16, 34-41.	0.4	2
50	Letter to the Editor: Intracranial hemorrhage and left ventricular assist devices. <i>Journal of Neurosurgery</i> , 2013, 119, 823-824.	0.9	0
51	Letters to the Editor: Spetzler-Martin Grade III arteriovenous malformations. <i>Journal of Neurosurgery</i> , 2013, 119, 820-822.	0.9	0
52	HeartWare miniaturized intrapericardial ventricular assist device: advantages and adverse events in comparison to contemporary devices. <i>Expert Review of Medical Devices</i> , 2013, 10, 441-452.	1.4	18
53	Implantation of rotary blood pumps into 115 patients: a single-centre experience. <i>European Journal of Cardio-thoracic Surgery</i> , 2013, 43, 1233-1236.	0.6	14
54	Mechanistic Pathway(s) of Acquired Von Willebrand Syndrome with a Continuous-Flow Ventricular Assist Device. <i>ASAIO Journal</i> , 2013, 59, 123-129.	0.9	54
55	Letters to the Editor: Severe traumatic brain injury. <i>Journal of Neurosurgery</i> , 2013, 119, 822-823.	0.9	0
56	The Evaluation of Leukocytes in Response to the In Vitro Testing of Ventricular Assist Devices. <i>Artificial Organs</i> , 2013, 37, 793-801.	1.0	21
57	Pulsatility and the Risk of Nonsurgical Bleeding in Patients Supported With the Continuous-Flow Left Ventricular Assist Device HeartMate II. <i>Circulation: Heart Failure</i> , 2013, 6, 517-526.	1.6	208
58	Rotary blood pumps as definitive treatment for severe heart failure. <i>Future Cardiology</i> , 2013, 9, 199-213.	0.5	5
59	Left Ventricular Assist Devices and Gastrointestinal Bleeding: A Narrative Review of Case Reports and Case Series. <i>Clinical Cardiology</i> , 2013, 36, 190-200.	0.7	85

#	ARTICLE	IF	CITATIONS
60	Theory to Predict Shear Stress on Cells in Turbulent Blood Flow. PLoS ONE, 2014, 9, e105357.	1.1	54
61	Antibody-based prevention of von Willebrand factor degradation mediated by circulatory assist devices. Thrombosis and Haemostasis, 2014, 112, 1014-1023.	1.8	37
62	Thromboresistance Comparison of the HeartMate II Ventricular Assist Device With the Device Thrombogenicity Emulation-Optimized HeartAssist 5 VAD. Journal of Biomechanical Engineering, 2014, 136, 021014.	0.6	73
63	Why pulsatility still matters: a review of current knowledge. Croatian Medical Journal, 2014, 55, 609-620.	0.2	41
64	The Effect of Shear Stress on the Size, Structure, and Function of Human von Willebrand Factor. Artificial Organs, 2014, 38, 741-750.	1.0	45
65	Ventricular assist devices in children. Current Opinion in Cardiology, 2014, 29, 113-121.	0.8	44
66	Current management of von Willebrand disease and von Willebrand syndrome. Current Opinion in Anaesthesiology, 2014, 27, 353-358.	0.9	13
67	Left Ventricular Assist Device Management in the ICU. Critical Care Medicine, 2014, 42, 158-168.	0.4	59
68	Acquired von Willebrand Syndrome in a Child Following Berlin Heart EXCOR Pediatric Ventricular Assist Device Implantation. World Journal for Pediatric & Congenital Heart Surgery, 2014, 5, 592-598.	0.3	13
69	Development of Acquired von Willebrand Syndrome During Short-Term Micro Axial Pump Support. ASAIO Journal, 2014, 60, 355-357.	0.9	28
70	Pre-Operative Risk Factors of Bleeding and Stroke During Left Ventricular Assist Device Support. Journal of the American College of Cardiology, 2014, 63, 880-888.	1.2	203
71	Dental treatment in the cardiothoracic intensive care unit for patients with ventricular assist devices awaiting heart transplant: a case series. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2014, 118, 194-201.	0.2	8
72	Are Centrifugal Ventricular Assist Devices the Answer to Reducing Post-Implantation Gastrointestinal Bleeding? —. JACC: Heart Failure, 2014, 2, 146-147.	1.9	9
73	Significantly Higher Rates of Gastrointestinal Bleeding and Thromboembolic Events With Left Ventricular Assist Devices. Clinical Gastroenterology and Hepatology, 2014, 12, 1461-1467.	2.4	60
74	Ambient hemolysis and activation of coagulation is different between HeartMate II and HeartWare left ventricular assist devices. Journal of Heart and Lung Transplantation, 2014, 33, 80-87.	0.3	99
75	Physiologic and hematologic concerns of rotary blood pumps: what needs to be improved?. Heart Failure Reviews, 2014, 19, 259-266.	1.7	16
76	Initial experience in Japan with HeartWare ventricular assist system. Journal of Artificial Organs, 2014, 17, 149-156.	0.4	9
77	ECMO-Extracorporeal Life Support in Adults. , 2014, , .		22

#	ARTICLE	IF	CITATIONS
78	Insights into the mechanism(s) of von Willebrand factor degradation during mechanical circulatory support. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 147, 1634-1643.	0.4	29
80	Left Ventricular Assist Device Management and Complications. <i>Critical Care Clinics</i> , 2014, 30, 607-627.	1.0	37
81	Acquired von Willebrand Syndrome in Patients With a Centrifugal or Axial Continuous Flow Left Ventricular Assist Device. <i>JACC: Heart Failure</i> , 2014, 2, 141-145.	1.9	192
82	Platelet glycoprotein Ib α ectodomain shedding and non-surgical bleeding in heart failure patients supported by continuous-flow left ventricular assist devices. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 71-79.	0.3	43
83	A History of Devices as an Alternative to Heart Transplantation. <i>Heart Failure Clinics</i> , 2014, 10, S1-S12.	1.0	21
84	High Shear Dependent von Willebrand Factor Self-assembly Fostered by Platelet Interaction and Controlled by ADAMTS13. <i>Thrombosis Research</i> , 2014, 133, 1079-1087.	0.8	25
85	Total Hip Arthroplasty in a Patient with a Left Ventricular Assist Device. <i>JBJS Case Connector</i> , 2014, 4, e61.	0.1	2
87	The Centrifugal Blood Pump as a Benchmark for In Vitro Testing of Hemocompatibility in Implantable Ventricular Assist Devices. <i>Artificial Organs</i> , 2015, 39, 93-101.	1.0	59
88	Circulatory support devices: fundamental aspects and clinical management of bleeding and thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1757-1767.	1.9	64
89	Gastrointestinal Bleeding during Continuous-Flow Left Ventricular Assist Device Support is Associated with Lower Rates of Cardiac Transplantation. <i>ASAIO Journal</i> , 2015, 61, 635-639.	0.9	21
90	Low Incidence of Gastrointestinal Bleeding and Pump Thrombosis in Patients Receiving the INCOR LVAD System in the Long-term Follow-up. <i>International Journal of Artificial Organs</i> , 2015, 38, 542-547.	0.7	14
91	Management of Pump Thrombosis in Patients with Left Ventricular Assist Devices. <i>American Journal of Cardiovascular Drugs</i> , 2015, 15, 89-94.	1.0	25
92	Pretransplant Coagulopathy and In-hospital Outcomes Among Heart Transplant Recipients: A Propensity-Matched Nationwide Inpatient Sample Study. <i>Clinical Cardiology</i> , 2015, 38, 300-308.	0.7	9
93	Treatment of the acquired von Willebrand syndrome. <i>Expert Review of Hematology</i> , 2015, 8, 799-818.	1.0	19
94	Fully Magnetically Levitated Left Ventricular Assist System for Treating Advanced HF. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2579-2589.	1.2	208
95	Coagulopathy in Mechanical Circulatory Support: A Fine Balance. <i>Current Cardiology Reports</i> , 2015, 17, 114.	1.3	15
96	Shear-induced platelet receptor shedding by non-physiological high shear stress with short exposure time: Glycoprotein Ib α and glycoprotein VI. <i>Thrombosis Research</i> , 2015, 135, 692-698.	0.8	58
97	Mechanical Stress Induced Blood Trauma. , 2015, , 305-333.		5

#	ARTICLE	IF	CITATIONS
98	Stroke After Left Ventricular Assist Device Implantation: Outcomes in the Continuous-Flow Era. <i>Annals of Thoracic Surgery</i> , 2015, 100, 535-541.	0.7	93
99	Hospital Readmissions After Continuous-Flow Left Ventricular Assist Device Implantation: Incidence, Causes, and Cost Analysis. <i>Annals of Thoracic Surgery</i> , 2015, 100, 884-889.	0.7	127
100	Extracorporeal Membrane Oxygenationâ€™ Hemostatic Complications. <i>Transfusion Medicine Reviews</i> , 2015, 29, 90-101.	0.9	329
101	Science for surgeons: Understanding pump thrombogenesis in continuous-flow left ventricular assist devices. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2015, 149, 667-673.	0.4	36
102	Antithrombotic therapy for left ventricular assist devices in adults: a systematic review. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 946-955.	1.9	61
103	Characteristics of Gastrointestinal Bleeding After Placement of Continuous-Flow Left Ventricular Assist Device: A Case Series. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1859-1867.	1.1	38
104	Octreotide in the Management of Recurrent Gastrointestinal Bleed in Patients Supported by Continuous Flow Left Ventricular Assist Devices. <i>ASAIO Journal</i> , 2015, 61, 107-109.	0.9	50
105	von Willebrand Factor as a Biological Sensor of Blood Flow to Monitor Percutaneous Aortic Valve Interventions. <i>Circulation Research</i> , 2015, 116, 1193-1201.	2.0	72
106	Inhibition of ADAMTS-13 by Doxycycline Reduces von Willebrand Factor Degradation During Supraphysiologicalâ€™Shearâ€™Stress. <i>JACC: Heart Failure</i> , 2015, 3, 860-869.	1.9	64
107	Antithrombotic therapy for ventricular assist devices in children: do we really know what to do?. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, S343-S350.	1.9	21
108	New Treatments for Left Ventricular Assist Device-Associated Bleeding? â€™. <i>JACC: Heart Failure</i> , 2015, 3, 870-872.	1.9	0
109	Intraplatelet reactive oxygen species, mitochondrial damage and platelet apoptosis augment non-surgical bleeding in heart failure patients supported by continuous-flow left ventricular assist device. <i>Platelets</i> , 2015, 26, 536-544.	1.1	19
110	Pre-Operative Right Ventricular Dysfunction Is Associated With Gastrointestinal Bleeding in Patients Supported With Continuous-Flow Leftâ€™Ventricular Assist Devices. <i>JACC: Heart Failure</i> , 2015, 3, 956-964.	1.9	63
111	Early postoperative management of heart transplant recipients with current ventricular assist device support in Japan: experience from a single center. <i>Journal of Anesthesia</i> , 2015, 29, 868-873.	0.7	2
112	Pathologic von Willebrand factor degradation with a left ventricular assist device occurs via two distinct mechanisms: Mechanical demolition and enzymatic cleavage. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2015, 149, 281-289.	0.4	96
113	Pathophysiology of Heart Failure and an Overview of Therapies. , 2016, , 271-339.		4
114	Mechanical Circulatory Support for Advanced Heart Failure: Are We about to Witness a New â€™Gold Standardâ€™?. <i>Journal of Cardiovascular Development and Disease</i> , 2016, 3, 35.	0.8	14
115	Mechanical circulatory assist devices: a primer for critical care and emergency physicians. <i>Critical Care</i> , 2016, 20, 153.	2.5	78

#	ARTICLE	IF	CITATIONS
116	Role of Antiplatelet Therapy and Anticoagulation in Nonischemic Cardiomyopathy. <i>Cardiology in Review</i> , 2016, 24, 211-217.	0.6	2
117	VAD. <i>JACC: Heart Failure</i> , 2016, 4, 971-973.	1.9	0
118	Reduced continuous-flow left ventricular assist device speed does not decrease von Willebrand factor degradation. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 151, 1747-1754.e1.	0.4	36
119	Bleeding and thrombosis in chronic ventricular assist device therapy. <i>Current Opinion in Cardiology</i> , 2016, 31, 299-307.	0.8	39
120	Acquired von Willebrand syndrome associated with left ventricular assist device. <i>Blood</i> , 2016, 127, 3133-3141.	0.6	185
121	Mechanical circulatory support is associated with loss of platelet receptors glycoprotein I β and glycoprotein VI. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 2253-2260.	1.9	83
122	Blood cell microparticles as biomarkers of hemostatic abnormalities in patients with implanted cardiac assist devices. <i>Biomarkers in Medicine</i> , 2016, 10, 1095-1104.	0.6	14
123	Evaluation of von Willebrand factor with a fully magnetically levitated centrifugal continuous-flow left ventricular assist device in advanced heart failure. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 860-867.	0.3	121
124	Effects of HeartWare ventricular assist device on the von Willebrand factor: results of an academic Belgian center. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 155.	0.7	5
125	In Vivo Evaluation of a Pneumatic Extracorporeal Ventricular Assist Device for up to 90 Day Support. <i>ASAIO Journal</i> , 2016, 62, 697-703.	0.9	1
126	The Diagnostic Yield of Repeated Endoscopic Evaluation in Patients with Gastrointestinal Bleeding and Left Ventricular Assist Devices. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1603-1610.	1.1	16
127	Rotary Blood Pumps as Long-Term Mechanical Circulatory Support: A Review of a 15-Year Berlin Experience. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2016, 28, 12-23.	0.4	13
129	Longitudinal changes in hemostatic parameters and reduced pulsatility contribute to non-surgical bleeding in patients with centrifugal continuous-flow left ventricular assist devices. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 743-751.	0.3	38
130	Acquired von Willebrand factor deficiency caused by LVAD is ADAMTS-13 and platelet dependent. <i>Thrombosis Research</i> , 2016, 137, 196-201.	0.8	48
131	Acquired Disorders of Platelet Function. , 2017, , 951-973.		1
132	Preservation of von Willebrand factor multimers and function in patients with an EVAHEART centrifugal-type, continuous-flow left ventricular assist device. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 814-817.	0.3	5
133	Bleeding and thrombosis associated with ventricular assist device therapy. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 1164-1173.	0.3	83
134	Pediatric Acquired von Willebrand Syndrome in Cardiopulmonary Disorders: Do Laboratory Abnormalities Predict Bleeding Risk?. <i>Journal of Pediatric Hematology/Oncology</i> , 2017, 39, 121-125.	0.3	8

#	ARTICLE	IF	CITATIONS
135	von Willebrand factor disruption and continuous-flow circulatory devices. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 1155-1163.	0.3	39
136	Comparative analysis of von Willebrand factor profiles after implantation of left ventricular assist device and total artificial heart. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1620-1624.	1.9	15
137	Mechanistic insight of platelet apoptosis leading to non-surgical bleeding among heart failure patients supported by continuous-flow left ventricular assist devices. <i>Molecular and Cellular Biochemistry</i> , 2017, 433, 125-137.	1.4	23
138	Emergency procedures for patients with a continuous flow left ventricular assist device. <i>Emergency Medicine Journal</i> , 2017, 34, 831-841.	0.4	13
139	Stopping LVAD Bleeding. <i>Circulation Research</i> , 2017, 121, 902-904.	2.0	17
140	Oxidative stress induced modulation of platelet integrin $\alpha 2\beta 1$ expression and shedding may predict the risk of major bleeding in heart failure patients supported by continuous flow left ventricular assist devices. <i>Thrombosis Research</i> , 2017, 158, 140-148.	0.8	19
141	Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels. <i>Blood</i> , 2017, 130, 2344-2353.	0.6	98
142	Scaling the Low-Shear Pulsatile TORVAD for Pediatric Heart Failure. <i>ASAIO Journal</i> , 2017, 63, 198-206.	0.9	21
143	Quantification of Von Willebrand Factor Cleavage by adamts-13 in Patients Supported by Left Ventricular Assist Devices. <i>ASAIO Journal</i> , 2017, 63, 849-853.	0.9	11
144	Shear Stress-Induced Total Blood Trauma in Multiple Species. <i>Artificial Organs</i> , 2017, 41, 934-947.	1.0	55
145	Inhaled Desmopressin for Refractory Gastrointestinal Bleeding in a Patient With a HeartMate II Left Ventricular Assist Device. <i>ASAIO Journal</i> , 2017, 63, e47-e49.	0.9	27
146	Constricted microfluidic devices to study the effects of transient high shear exposure on platelets. <i>Biomicrofluidics</i> , 2017, 11, 064105.	1.2	9
147	Existing issues and valid concerns in continuous-flow ventricular assist devices. <i>Expert Review of Medical Devices</i> , 2017, 14, 949-959.	1.4	4
148	Outcomes in HeartMate II Patients With No Antiplatelet Therapy: 2-Year Results From the European TRACE Study. <i>Annals of Thoracic Surgery</i> , 2017, 103, 1262-1268.	0.7	63
149	Shear-mediated platelet activation in the free flow: Perspectives on the emerging spectrum of cell mechanobiological mechanisms mediating cardiovascular implant thrombosis. <i>Journal of Biomechanics</i> , 2017, 50, 20-25.	0.9	61
150	Left Ventricular Assist Device Design Reduces von Willebrand Factor Degradation: A Comparative Study Between the HeartMate II and the EVAHEART Left Ventricular Assist System. <i>Annals of Thoracic Surgery</i> , 2017, 103, 1239-1244.	0.7	47
151	Acquired von Willebrand Syndrome in IgM Monoclonal Gammopathy as the Presentation of Lymphoplasmacytic Lymphoma. <i>Case Reports in Hematology</i> , 2017, 2017, 1-5.	0.3	3
152	Acquired von Willebrand syndrome in cardiogenic shock patients on mechanical circulatory microaxial pump support. <i>PLoS ONE</i> , 2017, 12, e0183193.	1.1	33

#	ARTICLE	IF	CITATIONS
153	Clinical Relevance of Histopathologic Analysis of HeartMate II Thrombi. <i>ASAIO Journal</i> , 2018, 64, 754-759.	0.9	15
154	Advances in Left Ventricular Assist Devices and Mechanical Circulatory Support. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2018, 32, 1193-1213.	0.6	16
155	Gastrointestinal Bleeding in Left Ventricular Assist Device: Octreotide and Other Treatment Modalities. <i>ASAIO Journal</i> , 2018, 64, 433-439.	0.9	31
156	Von Willebrand factor multimer quantitation for assessment of cardiac lesion severity and bleeding risk. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 155-161.	1.0	3
157	Prospective analysis of bleeding events in left ventricular assist device patients. <i>International Journal of Artificial Organs</i> , 2018, 41, 269-276.	0.7	5
158	Left Ventricular Assist Device Therapy for Destination Therapy: Is Less Invasive Surgery a Safe Alternative?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018, 71, 13-17.	0.4	12
159	Association of Oxidative Stress and Platelet Receptor Glycoprotein GPIb β and GPVI Shedding During Nonsurgical Bleeding in Heart Failure Patients With Continuous-Flow Left Ventricular Assist Device Support. <i>ASAIO Journal</i> , 2018, 64, 462-471.	0.9	13
160	Mechanisms of Platelet Dysfunction in Patients with Implantable Devices. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 012-019.	1.5	5
161	Asistencia ventricular izquierda como terapia de destino: ¿la cirugía mínimamente invasiva es una alternativa segura?. <i>Revista Espanola De Cardiologia</i> , 2018, 71, 13-17.	0.6	19
162	Routine clinical anti-platelet agents have limited efficacy in modulating hypershear-mediated platelet activation associated with mechanical circulatory support. <i>Thrombosis Research</i> , 2018, 163, 162-171.	0.8	15
163	Perioperative Management of the Patient With a Left Ventricular Assist Device for Noncardiac Surgery. <i>Anesthesia and Analgesia</i> , 2018, 126, 1839-1850.	1.1	15
164	Minimally invasive surgery improves outcome of left ventricular assist device surgery in cardiogenic shock. <i>Journal of Thoracic Disease</i> , 2018, 10, S1696-S1702.	0.6	39
165	Continuous-Flow Left Ventricular Assist Device-Related Gastrointestinal Bleeding. <i>Cardiology Clinics</i> , 2018, 36, 519-529.	0.9	18
166	The Hemodynamic Profile of GI Bleeding in Continuous-Flow LVADs: Is it All About the Right Ventricle?. <i>Journal of Cardiac Failure</i> , 2018, 24, 494-495.	0.7	0
167	Acquired Von Willebrand Syndrome and Blood Pump Design. <i>Artificial Organs</i> , 2018, 42, 1119-1124.	1.0	15
168	Antithrombotic Strategies and Device Thrombosis. <i>Cardiology Clinics</i> , 2018, 36, 541-550.	0.9	12
169	Von Willebrand factor and the aortic valve: Concepts that are important in the transcatheter aortic valve replacement era. <i>Thrombosis Research</i> , 2018, 170, 20-27.	0.8	5
170	Pharmacotherapy considerations for long-term management of patients with left ventricular assist devices. <i>American Journal of Health-System Pharmacy</i> , 2018, 75, 755-766.	0.5	7

#	ARTICLE	IF	CITATIONS
171	Medical management of the supported patient. , 2018, , 529-564.		0
172	Speed Modulation of the HeartWare HVAD to Assess In Vitro Hemocompatibility of Pulsatile and Continuous Flow Regimes in a Rotary Blood Pump. <i>Artificial Organs</i> , 2018, 42, 879-890.	1.0	18
173	In Vitro Hemocompatibility Evaluation of Ventricular Assist Devices in Pediatric Flow Conditions: A Benchmark Study. <i>Artificial Organs</i> , 2018, 42, 1028-1034.	1.0	15
175	Speed Reduction Does Not Restore High Molecular Weight von Willebrand Multimers During HeartMate II Support: An In Vivo Study. <i>ASAIO Journal</i> , 2018, 64, e123-e125.	0.9	5
176	Complications of Durable Left Ventricular Assist Device Therapy. <i>Critical Care Clinics</i> , 2018, 34, 465-477.	1.0	9
177	Medical Therapy As Compared To Surgical Device Exchange for Left Ventricular Assist Device Thrombosis: A Systematic Review and Meta-Analysis. <i>ASAIO Journal</i> , 2019, 65, 307-317.	0.9	30
178	Long-term evaluation of a fully magnetically levitated circulatory support device for advanced heart failure—two-year results from the HeartMate 3â€œCE Mark Study. <i>European Journal of Heart Failure</i> , 2019, 21, 90-97.	2.9	78
179	High-frequency operation of pulsatile ventricular assist devices: A computational study on circular and elliptically shaped pumps. <i>International Journal of Artificial Organs</i> , 2019, 42, 725-734.	0.7	2
180	Outcomes After Intracranial Hemorrhage in Patients with Left Ventricular Assist Devices: A Systematic Review of Literature. <i>World Neurosurgery</i> , 2019, 132, 265-272.	0.7	14
181	Acquired von Willebrand syndrome in patients treated with veno-arterial extracorporeal membrane oxygenation. <i>Cardiovascular Intervention and Therapeutics</i> , 2019, 34, 358-363.	1.2	15
182	Stroke after implantation of continuous flow left ventricular assist devices. <i>Journal of Cardiac Surgery</i> , 2019, 34, 541-548.	0.3	13
183	Left ventricular assist devices and their complications: A review for emergency clinicians. <i>American Journal of Emergency Medicine</i> , 2019, 37, 1562-1570.	0.7	57
184	Early signatures of bleeding and mortality in patients on left ventricular assist device support: novel methods for personalized risk-stratification. <i>Biomarkers</i> , 2019, 24, 448-456.	0.9	3
185	Acquired Disorders of Platelet Function. , 2019, , 905-920.		2
186	Evaluation of anticoagulation and nonsurgical major bleeding in recipients of continuous-flow left ventricular assist devices. <i>Artificial Organs</i> , 2019, 43, 736-744.	1.0	7
187	Device-induced platelet dysfunction in mechanically assisted circulation increases the risks of thrombosis and bleeding. <i>Artificial Organs</i> , 2019, 43, 745-755.	1.0	31
188	Third-Generation LVADs. <i>Cardiology in Review</i> , 2019, 27, 293-301.	0.6	13
189	Management of Antiplatelet Therapy During Continuous-Flow Left Ventricular Assist Device Support After Thrombotic Hemorrhagic Events. <i>ASAIO Journal</i> , 2019, 65, 683-689.	0.9	5

#	ARTICLE	IF	CITATIONS
190	The Predicament of Gastrointestinal Bleeding in Patients With a Continuous-Flow Left Ventricular Assist Device. <i>Cardiology in Review</i> , 2019, 27, 222-229.	0.6	3
191	In vitro comparison of the hemocompatibility of two centrifugal left ventricular assist devices. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 157, 591-599.e4.	0.4	19
192	Medical Management of Left Ventricular Assist Device Patients: A Practical Guide for the Nonexpert Clinician. <i>Canadian Journal of Cardiology</i> , 2020, 36, 205-215.	0.8	9
193	Miniaturized Test Loop for the Assessment of Blood Damage by Continuous-Flow Left-Ventricular Assist Devices. <i>Annals of Biomedical Engineering</i> , 2020, 48, 768-779.	1.3	9
194	SSRI/SNRI Therapy is Associated With a Higher Risk of Gastrointestinal Bleeding in LVAD Patients. <i>Heart Lung and Circulation</i> , 2020, 29, 1241-1246.	0.2	12
195	The Role of a Disintegrin and Metalloproteinase Proteolysis and Mechanical Damage in Nonphysiological Shear Stress-Induced Platelet Receptor Shedding. <i>ASAIO Journal</i> , 2020, 66, 524-531.	0.9	5
196	Device-related epistaxis risk: continuous-flow left ventricular assist device-supported patients. <i>European Archives of Oto-Rhino-Laryngology</i> , 2020, 277, 2767-2773.	0.8	1
197	Characterization and timing of gastrointestinal bleeding in continuous flow left ventricular assist device recipients. <i>Heliyon</i> , 2020, 6, e04695.	1.4	9
199	Decreased RPM reduces von Willebrand factor degradation with the EVAHEART LVAS: implications for device-specific LVAD management. <i>Journal of Cardiac Surgery</i> , 2020, 35, 1477-1483.	0.3	9
200	Anticoagulant treatment and bleeding complications in patients with left ventricular assist devices. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 363-372.	0.6	22
201	Device-Induced Hemostatic Disorders in Mechanically Assisted Circulation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962098237.	0.7	29
202	A Comprehensive Review of Risk Factor, Mechanism, and Management of Left Ventricular Assist Device-Associated Stroke. <i>Seminars in Neurology</i> , 2021, 41, 411-421.	0.5	2
203	The EHA Research Roadmap: Platelet Disorders. <i>HemaSphere</i> , 2021, 5, e601.	1.2	3
204	Acquired von Willebrand Syndrome. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 1103-1116.	0.9	12
205	Association of thrombophilia prospective detection with hemocompatibility related outcomes in left ventricular assist device patients. <i>International Journal of Artificial Organs</i> , 2021, 44, 039139882110416.	0.7	1
206	Toward a Standard Practice to Quantify von Willebrand Factor Degradation During Left Ventricular Assist Device Support. <i>Annals of Thoracic Surgery</i> , 2021, 112, 1257-1264.	0.7	12
207	Mechanische Herzunterstützungssysteme. , 2017, , 555-577.		1
208	Trends, predictors and outcomes of ischemic stroke and intracranial hemorrhage in patients with a left ventricular assist device. <i>Annals of Translational Medicine</i> , 2018, 6, 5-5.	0.7	29

#	ARTICLE	IF	CITATIONS
209	Mechanical circulatory support systems: evolution, the systems and outlook. Cardiovascular Diagnosis and Therapy, 2021, 11, 309-322.	0.7	5
210	Bleeding with the artificial heart: Gastrointestinal hemorrhage in CF-LVAD patients. World Journal of Gastroenterology, 2017, 23, 3945.	1.4	50
211	Treatment of Advanced Heart Failure: Beyond Medical Treatment. Korean Journal of Medicine, 2012, 82, 658.	0.1	2
212	Mechanical circulatory support devices as destination therapy-current evidence. Annals of Cardiothoracic Surgery, 2014, 3, 513-24.	0.6	22
213	Facilitating noncardiac surgery for the patient with left ventricular assist device: A guide for the anesthesiologist. Annals of Cardiac Anaesthesia, 2018, 21, 351.	0.3	13
214	Increased Incidence of Angiodysplasia of the Gastrointestinal Tract and Bleeding in Patients with Continuous Flow Left Ventricular Assist Devices (LVADs). International Journal of Artificial Organs, 2013, 36, 449-454.	0.7	15
215	Interactions of von Willebrand factor and ADAMTS13 in von Willebrand disease and thrombotic thrombocytopenic purpura. Hamostaseologie, 2014, 34, 215-225.	0.9	15
216	VAD-Nachsorge. , 2013, , 235-281.		0
217	Left Ventricular Assist Devices: From Bridge to Transplant to Destination Therapy. , 2013, , 385-423.		0
218	Komplikationsmanagement. , 2013, , 283-332.		0
219	Treatment Options for End-Stage Cardiac Failure. , 2014, , 217-235.		0
220	Mechanische Herzunterstützungssysteme. , 2015, , 1-23.		1
221	Association of Blood Group O with Gastrointestinal Bleeding in Continuous-Flow LVAD Patients. British Journal of Medicine and Medical Research, 2015, 9, 1-6.	0.2	0
222	Postoperatives VAD-Management. , 2017, , 161-223.		1
224	Medical Management of the Patient with Chronic Mechanical Circulatory Support. , 2017, , 665-690.		0
225	Coagulation Monitoring. , 2017, , 433-443.		0
226	Mechanical Circulatory Support as a Bridge to Heart Transplantation. , 2017, , 639-663.		0
227	Acquired von Willebrand Syndrome. , 2017, , 539-544.		0

#	ARTICLE	IF	CITATIONS
228	Epidemiology of Cardiac Surgery and the Cardiac Surgical Patient. , 2019, , 266-280.		0
229	Analysis of hemorrhagic and thromboembolic complications in patients with implanted left ventricular assist devices. Emergency Medicine, 2019, .	0.0	0
230	Hemorrhagic and thromboembolic complications in patients with implanted left ventricular assist devices in early postoperative period. Pain Anesthesia and Intensive Care, 2019, .	0.1	0
231	Therapy Management of VADs. , 2020, , 147-167.		0
232	Ventricular Assist Device as Bridge-to-Transplant. Organ and Tissue Transplantation, 2020, , 1-9.	0.0	0
233	Ventricular Assist Device as Bridge-to-Transplant. Organ and Tissue Transplantation, 2020, , 85-93.	0.0	0
234	End-Organ Physiology Under Continuous-Flow Mechanical Circulatory Support. , 2020, , 279-300.		0
235	Left Ventricular Assist Devices and Pacemakers. , 2020, , 165-192.		0
236	Anesthesia in Patient with Left Ventricular Assist Device Support. A Case Report.. Albanian Journal of Trauma and Emergency Surgery, 2020, 4, 716-719.	0.1	0
237	Epidemiology of Cardiac Surgery and the Cardiac Surgical Patient. Advances in Medical Technologies and Clinical Practice Book Series, 0, , 1-15.	0.3	0
238	Gastrointestinal bleed after left ventricular assist device implantation: incidence, management, and prevention. Annals of Cardiothoracic Surgery, 2014, 3, 475-9.	0.6	70
240	Primary Diagnoses and Relative Risk in Patients With Left Ventricular Assist Devices Visiting an Emergency Department in the United States. Journal of the American Heart Association, 2022, 11, e024228.	1.6	0
242	Hydrodynamic Impact on Blood: From Left Ventricular Assist Devices to Artificial Hearts. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 481-483.	1.1	1
243	Role of acquired von Willebrand syndrome in the development of bleeding complications in patients treated with Impella RP devices. Scientific Reports, 2021, 11, 23722.	1.6	4
244	Physiology of Continuous-Flow Left Ventricular Assist Device Therapy. , 2021, 12, 2731-2767.		3
246	(Physiology of Continuous-flow Left Ventricular Assist Device Therapy. Translation of the document) Tj ETQq1 1 0.784314 rgBT /Over	0.1	0
247	The Von Willebrand factor-ADAMTS-13 axis: a two-faced Janus in bleeding and thrombosis. , 2022, 1, .		0
248	Acquired platelet defects are responsible for nonsurgical bleeding in left ventricular assist device recipients. Artificial Organs, 2022, 46, 2244-2256.	1.0	7

#	ARTICLE	IF	CITATIONS
249	Pathophysiology of heart failure and an overview of therapies. , 2022, , 149-221.		1
250	Left ventricular assist device-related infections and the risk of cerebrovascular accidents: a EUROMACS study. European Journal of Cardio-thoracic Surgery, 2022, 62, .	0.6	3
251	Acquired von Willebrand syndrome: Five cases report and literature review. Thrombosis Research, 2022, 218, 145-150.	0.8	2
252	Acquired von Willebrand syndrome and hemocompatibility-related adverse events in patients with left ventricular assist device. Journal of Biorheology, 2022, 36, 12-22.	0.2	0
253	Bleeding and thrombotic complications and their impact on mortality in patients supported with left ventricular assist device for cardiogenic shock. Perfusion (United Kingdom), 0, , 026765912211276.	0.5	0
254	Artificial Muscles and Soft Robotic Devices for Treatment of Endâ€Stage Heart Failure. Advanced Materials, 2023, 35, .	11.1	9
255	Gastrointestinal bleeding in patients with continuousâ€flow left ventricular assist devices: A comprehensive review. Artificial Organs, 2023, 47, 12-23.	1.0	6
256	The Role of the von Willebrand Factor Collagen-Binding Assay (VWF:CB) in the Diagnosis and Treatment of von Willebrand Disease (VWD) and Way Beyond: A Comprehensive 36-Year History. Seminars in Thrombosis and Hemostasis, 2024, 50, 043-080.	1.5	2